HCR Haematological complete remission IDA Idarubicin ITT Intention-to-treat IV Intravenous mRNA Messenger ribonucleic acid MTX Methotrexate NCCN National Comprehensive Cancer Network NCI National Cancer Institute ND Not done OS Overall survival PML-RARα Promyelocytic leukaemia retinoic acid receptor alpha fusion gene – PP Per protocol QTc Corrected QT interval RCT Randomised controlled RFS Relapse free survival RT-PCR Reverse transcriptase-polymerase chain reaction SAE Serious adverse event TE Thromboembolism TGA Therapeutic Administration TTR Time to relapse VZV Varicella Zoster Virus WBC White blood cell count
HCR Haematological complete remission IDA Idarubicin ITT Intention-to-treat IV Intravenous mRNA Messenger ribonucleic acid MTX Methotrexate NCCN National Comprehensive Cancer Network NCI National Cancer Institute ND Not done OS Overall survival PML-RARα Promyelocytic leukaemia – retinoic acid receptor alpha fusion gene PP Per protocol QTc Corrected QT interval RCT Randomised controlled RFS Relapse free survival RT-PCR Reverse transcriptase-polymerase chain reaction SAE Serious adverse event TE Thromboembolism TGA Therapeutic Administration TTR Time to relapse VZV Varicella Zoster Virus WBC White blood cell count